STR genotyping confirms gestational origin of pelvic choriocarcinoma, guiding risk score revisionGenetic testing helps identify the source of rare tumors
Frontiers in MedicinePublished August 5, 2026Study authors: He Qiu, Tingting Chen, Fenghua Ma, Weiguo Hu, Xin Lu, Jiahui Ma, Yan Du, Xiaoni YueDOI ↗Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider STR genotyping to confirm tumor origin and refine risk stratification in extrauterine choriocarcinoma.
This case report details the clinical course of a 29-year-old woman with pelvic gestational choriocarcinoma, a rare extrauterine presentation. The authors used short tandem repeat (STR) genotyping to determine the tumor's origin, which revealed a homozygous androgenetic diploid pattern, confirming that the tumor originated from a complete hydatidiform mole. This molecular diagnosis allowed for a revision of the prognostic risk score from 9 to 8, which is clinically significant as it may affect treatment planning and risk stratification.
The patient underwent emergency laparoscopy, three-dimensional laparoscopic resection of the lesion, and chemotherapy. Following treatment, serum human chorionic gonadotropin (hCG) normalized, and the patient remained disease-free at 25 months of follow-up. The report highlights the utility of STR genotyping in cases where the primary tumor site is uncertain, as it provides definitive etiological classification.
The authors note a limitation: the initial resected tissue was insufficient for STR genotyping, necessitating additional tissue sampling. This underscores the importance of obtaining adequate tissue for molecular analysis in such cases.
While the outcome is favorable, this is a single case report and does not establish general clinical guidelines. However, it supports the value of STR genotyping for etiological classification and risk stratification in extrauterine choriocarcinoma, and suggests that surgical resection of isolated lesions can provide tissue for molecular diagnosis. Clinicians encountering similar cases may consider this approach, but broader evidence is needed.
How this fits prior evidence
This case report extends prior coverage by demonstrating a specific application of molecular diagnostics in a rare cancer type. While prior items focused on systemic therapies in common cancers (e.g., chemoimmunotherapy in LCNEC, ICIs plus chemotherapy in TNBC), this case highlights the role of STR genotyping in refining diagnosis and risk stratification in gestational choriocarcinoma. It addresses a gap by showing how molecular techniques can guide individualized treatment decisions, complementing the broader theme of precision oncology evident in prior coverage.
When a patient is diagnosed with a rare type of cancer called choriocarcinoma, doctors need to know exactly where it started. Knowing the source helps them decide on the best way to treat the disease and predict how it might behave in the future.
A 29-year-old woman was treated for this condition using surgery and chemotherapy. Because her initial tissue sample was too small for testing, doctors used a special genetic test called STR genotyping. This test looked at her DNA to find the tumor's origin. It confirmed that her cancer came from a specific type of pregnancy-related growth called a complete hydatidiform mole.
The results were positive. Her hormone levels returned to normal, and she remained free of the disease for 25 months after treatment. While this was just one case, it shows how genetic testing can help doctors better understand a patient's specific risk and choose the right path forward.
What this means for you:
Genetic testing can pinpoint the origin of rare tumors to help doctors provide more accurate care.
Common questions
What did the genetic test reveal about the patient's condition?
The STR genotyping test revealed a homozygous androgenetic diploid pattern. This result confirmed that the tumor originated from a complete hydatidiform mole, which helped doctors determine the exact source of her cancer.
How did the patient respond to treatment?
The patient responded well to surgery and chemotherapy. Her serum hCG levels normalized, and she remained free of disease for 25 months during the follow-up period.
Why is identifying the tumor's origin important?
Identifying the source through STR genotyping helps doctors with etiological classification. This means they can better understand the cause and provide a more accurate risk score for the patient's future health.
Pelvic gestational choriocarcinoma (GCC) is very rare. It may mimic ectopic pregnancy because of the elevated human chorionic gonadotropin (hCG) levels and absence of typical uterine lesions. After choriocarcinoma is identified, accurate determination of tumor origin is critical for prognostic risk stratification and treatment selection.
A 29-year-old woman presented with irregular vaginal bleeding and markedly rising hCG levels, with imaging revealing a pelvic mass, and was initially diagnosed with ectopic pregnancy. Emergency laparoscopy and pathological review confirmed choriocarcinoma, but the resected tissue was insufficient for short tandem repeat (STR) genotyping to determine the tumor origin. Based on her pregnancy history and age, she was empirically treated for presumed GCC and achieved complete remission after chemotherapy. Approximately 3 years later, she developed an isolated recurrence at the same location. She then underwent three-dimensional laparoscopic resection, which enabled STR genotyping. The analysis revealed a homozygous androgenetic diploid pattern, definitively confirming gestational origin and establishing the causative gestation as a complete hydatidiform mole, thereby revising the prognostic score from 9 to 8. Postoperatively, the patient received five cycles of chemotherapy, serum hCG normalized, and she remains disease-free at 25 months of follow-up.
The case underscores two key messages. First, STR genotyping is highly valuable for accurate etiological classification and risk stratification in extrauterine choriocarcinoma. Second, surgical resection of an isolated chemoresistant or recurrent lesion, even at elevated hCG levels, can provide essential tissue for molecular diagnosis and facilitate rapid biochemical remission.
